Class I-restricted CD8+ cytotoxic T lymphocytes (CTL) are major components of antiviral immunity, particularly for recovery from infection (21, 25). In consequence, understanding how to best induce and control CTL is relevant in vaccine design. CTL usually recognize peptides derived from viral proteins synthesized within the cell in the context of major histocompatibility complex class I molecules (5, 13, 18, 34). In many cases, a few specific peptide fragments derived from only a single viral protein appear to dominate the response (4). Immunodominance of specific amino acid residues or epitopes in induction of CTL responses may depend upon the affinity of a peptide for major histocompatibility complex molecules, as well as the T-cell repertoire in the responding strain (3, 8) . Identification of CTL epitopes and understanding how to induce CTL responses with them are, therefore, important aspects of vaccine development.
Class I-restricted CD8+ cytotoxic T lymphocytes (CTL) are major components of antiviral immunity, particularly for recovery from infection (21, 25) . In consequence, understanding how to best induce and control CTL is relevant in vaccine design. CTL usually recognize peptides derived from viral proteins synthesized within the cell in the context of major histocompatibility complex class I molecules (5, 13, 18, 34) . In many cases, a few specific peptide fragments derived from only a single viral protein appear to dominate the response (4) . Immunodominance of specific amino acid residues or epitopes in induction of CTL responses may depend upon the affinity of a peptide for major histocompatibility complex molecules, as well as the T-cell repertoire in the responding strain (3, 8) . Identification of CTL epitopes and understanding how to induce CTL responses with them are, therefore, important aspects of vaccine development.
A limiting factor in the use of viral proteins or peptides as vaccines is that following administration they readily induce CD4+ T-cell and antibody responses but usually fail to induce CD8+ CTL (25) . The endogenous synthesis requirement for CD8+ CTL induction could be bypassed if antigen were delivered to an appropriate cytosolic compartment of antigen-presenting cells (10, 17, 20, 23, 26, 29, 30) . One such approach is osmotic loading, found useful with ovalbumin and other soluble proteins (17) . Delivery of proteins by means of immunostimulating complexes may also effect CTL priming (29) . Certain peptides may be rendered CTL inducing if given with powerful adjuvants, such as Freund's or following modification by covalently coupling them to acyl groups (1, 10, 12, 26, 27) . Recently, we have shown that nontoxic liposomes can be used to achieve CTL recognition * Corresponding author.
of soluble proteins (23) . Moreover, if liposomes designed to disrupt under acid conditions (pH-sensitive liposomes) were used to deliver antigen to dendritic cells (DC), a delivery system capable even of primary CTL induction in vitro was obtained (19) . In this study, we used the in vitro primary CTL induction approach to explore optimal and potentially practical means of inducing CTL responses to herpes simplex virus type 1 (HSV-1). Glycoprotein B (gB) of HSV was chosen for this study since this protein was shown recently to act as a major CTL target in H-2b mice and a region (amino acids [aa] 489 to 515) that represents an immunodominant epitope has been identified (14, 32) . Our results show that delivery of gB protein or gB peptide to DC, but not to macrophages (M0), results in primary HSV-specific CTL responses. Moreover, optimal responses occurred when soluble proteins were delivered via liposomes and when the peptide was presented as the tripalmitoyl-S-glyceryl cysteinyl (PAM3Cys) derivative. Our results set the stage for practical means of inducing antiviral CTL responses and are based on an approach useful for rapid evaluation of the CTL-inducing activities of proteins and peptides. -CH-CO-THR-SER-SER-ILE-GLU-PHE-ALA-ARG-LEU-GLN-PHE-THR-TYR- (1:1) to remove impurities (higher Rf on silica gel 60 thln-layer chromatography) and then with chloroform to elute the product. Any remaining palmitic acidcontaining impurities were removed by flash chromatography over silica gel 60 using hexane-ether (1:1) to elute the rac-PAM3Cys tert-butyl ester.
INDUCTION OF PRIMARY ANTIVIRAL IMMUNE RESPONSES
The above-described products and intermediates gave single spots by thin-layer chromatography and satisfactory melting points, proton magnetic resonance spectra, and MS data.
Peptide synthesis. The HSV-1 gB peptide (aa 497 to 510) was synthesized by solid-phase methodology on a glycyl-4-(hydroxymethyl)phenoxyacetyl polystyrene resin with an automated Applied Biosystems 431A peptide synthesizer with 9-fluorenylmethoxycarbonyl a-amino protection-based chemistry. The core sequence was Thr-Ser-Ser-Ile-Glu-PheAla-Arg-Leu-Gln-Phe-Thr-Tyr.
The amino acid side chain protection included t-butyl for threonine, tyrosine, and serine hydroxyls; t-butyl for glutamic y-carboxyl; 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl for the guanidino group of arginine; and t-butyl for the cysteine sulfhydryl.
For the PAM3Cys-HSV-1 peptide derivative ( Fig. 1) , the amino-terminal threonine was deprotected with a 20% solution of piperidine in N-methylpyrrolidinone. The peptidyl resin (100 mg), containing 24 p,mol of peptide, was treated with 2 ml of an N-methylpyrrolidinone solution containing 32 mg (34.5 p,mol) of PAM3Cys, 15 .93 mg (36 ,umol) of benzotriazol-1-yloxytris-(dimethylamino)-phosphonium hexafluorophosphate, 5.5 mg (36 ,mol) of 1-hydroxybenzotriazole, and 5.7 pi (52 pRmol) of N-methylmorpholine. The mixture was shaken overnight, and the extent of coupling was found to be 95%, as determined by ninhydrin analysis of residual free amino groups. The peptidyl resin was filtered, washed with N-methylpyrrolidinone and dichloromethane, and dried. The PAM3Cys-HSV peptide was cleaved from the resin by treatment with a mixture of 5 ml of trifluoroacetic acid (TFA), 0.25 ml of thioanisole, and 0.125 ml of water for 2 h at room temperature. The mixture was filtered, evaporated to dryness, and dissolved in 5 ml of dichloromethane. A 25-ml volume of acetone was added, and the mixture was kept at -20°C overnight. The precipitate was collected, dissolved in a minimal amount of N-methylpyrrolidinone, and purified by reversed-phase chromatography with a VyDac C4 column with a mobile phase consisting of 20 to 80% isopropanol (containing 0.05% TFA) in 0.05% aqueous TFA buffer. The purified HSV peptide gave the correct amino acid analysis and the predicted parent ion by MS analysis (predicted mass, 2,512.6; observed mass, 2,512.1).
For the N-palmitoylated derivative, S-(t-butyl)-cysteine was added to the amino-terminal threonine of the peptidyl resin, followed by acylation with palmitic anhydride (2 equivalents). The N-palmitoylated peptide was cleaved from the resin (100 mg) by treatment with a solution of TFA (5 ml) containing phenol (6.3%), ethanedithiol (2%), thioanisole (4%), and water (4%). After 1.5 h at room temperature, the mixture was filtered, the resin was washed with a few milliliters of TFA, and the acyl peptide was precipitated by addition of a mixture of methyl tert-butyl ether (30 ml) and hexane (10 ml) prechilled to -20°C. The peptide was collected by centrifugation, and the precipitate was triturated twice with 40 ml of a chilled methyl tert-butyl ether-hexane (3:1) solution to remove scavengers. The acyl peptide was dried under high vacuum and used without further purification. It gave the expected amino acid composition and parent ion by MS analysis.
Lipids. Dioleoyl phosphatidylethanolamine, dioleoyl-Sn-3-succinyl glycerol, phosphatidylcholine, cholesterol, and phosphatidylserine, used to prepare liposomes, were obtained from Avanti Polar Lipids, Birmingham, Ala. Labeling of antigen with125I was done with lodogen (Pierce Chemical Co., Rockford, Ill.).
Preparation of liposomes. Dioleoyl phosphatidylethanolamine and dioleoyl-Sn-3-succinyl glycerol (10,umol of total lipid) were used to make pH-sensitive liposomes containing gB protein as described elsewhere (33) . Briefly, the lipid mixture was dried with N2 gas and vacuum desiccated. The lipid film was resuspended in 50pul of 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer, Antigen-presenting cells (APC) and responder T cells. Splenocytes obtained from naive C57BL/6 female retired breeders were treated with ammonium chloride-containing Tris buffer for 3 min to deplete erythrocytes. Splenocytes (3 ml), at 2 x 107/ml, were layered over a 2-ml metrizamide gradient column (analytical grade; 14.5 g added to 100 ml of PBS, pH 7.0; Nycomed Pharma AS, Oslo, Norway) and centrifuged at 600 x g for 10 in 5% CO2 for 4 h. A 100-pA volume of the supernatant fluid was collected to measure radioactivity, and specific cytotoxic activity was determined with the following formula: % specific release = [(experimental release -spontaneous release)/(total release -spontaneous release)] x 100. Each assay was performed in triplicate, and the spontaneous release was less than 25% of the total release by detergent in all assays. Fig. 2A and B, unstimulated cells contained both CD4+ and CD8+ T cells but none additionally expressed PgP-1. However, after antigen stimulation, both CD4+ PgP+ and CD8+ PgP+ cells were present (Fig. 2C, D , and E). Of the two populations, CD4+ PgP+ cells predominated, but with all of the systems studied, CD8+ PgP+ cells were also present. Although the antigen specificity characteristics of proliferating cells were not analyzed, the CD8+ PgP+ population presumably represented the precursors of the CTL described below.
Induction of in vitro primary CTL responses. Microcultures of antigen-pulsed APC and naive responder T cells were established in Terasaki plates, and cultures were harvested after 5 days for measurement of HSV-specific and peptide-specific CTL responses. Optimal responses were obtained at an R/S ratio of 25:1, and all of the data in Table  2 reflect these conditions. As shown in Table 2 , CTL responses were generated but only when DC were used as APC. This was further established by treating DC pulsed with HSV-1 with MAb 33D1 and complement in vitro to deplete DC, which effectively removed the CTL-inducing activity of the cell population (data not shown). Major histocompatibility complex class I-restricted anti-HSV-1 responses were induced in T cells stimulated with DC pulsed with HSV-1, gB protein, or H-2b-recognized gB peptide 497-510. Cytotoxicity did not occur in cultures with DC pulsed with control gD peptide 1-23. DC pulsed with gD peptide in MLV, however, did induce proliferative responses (Table 1) . Cytotoxicity was also detected in the HSV-positive cultures by using targets pulsed with H-2"-recognizable minimal peptide 498-505, although not by using targets pulsed with H-2"-recognizable peptide 280-288. In separate experiments, peptides 498-505 and 280-288 were also used to induce CTL responses. Both HSV-specific and peptide-specific responses were induced by gB peptide 498-505 but not by 280-288 (Table 3) . In these experiments, DC were pulsed with peptides in vitro. Also shown in Table 3 is the fact that DC pulsed with vaccinia virus expressing gB protein in vitro stimulated potent anti-HSV-1 and peptidespecific cytotoxic responses.
Liposome incorporation was necessary to obtain CTL responses with the gB protein antigen (Table 2) . In this instance, liposomes were of the pH-sensitive type since previous studies with ovalbumin had shown that pH-sensitive liposomes are superior to insensitive MLV for CTL induction (19) . With peptide 497-510, primary CTL induction occurred with DC from animals exposed to either free peptide or liposome-delivered peptide. The latter form was, however, marginally superior. Consistently superior CTL responses were obtained in cultures with DC from animals pulsed with PAM3Cys-peptide in liposomes. Since this form of the peptide was insoluble in aqueous buffers, it was not administered to animals in the nonliposomal form. In three separate experiments, in addition to that whose results are given in Table 2 , PAM3Cys-peptide routinely induced greater HSV-1-specific and peptide-specific responses than did the other immunogens investigated. 
DISCUSSION
In this study, we confirmed the identity of a major CTL-recognizable epitope on gB of HSV-1 in H-2' mice and showed the minimal peptide capable of inducing a primary CTL response in vitro (Table 3 (15, 16) , that permitted dense cell concentrations. In most instances, DC were primed by injection of antigen in vivo, followed after 3 h by isolation of DC from the spleens of such antigen-pulsed animals. This approach was used since previous studies with ovalbumin had indicated that antigen pulsing of DC in vivo is more effective than antigen pulsing in vitro (19) , but the reasons for the greater efficacy of in vivo exposure were not elucidated.
It is becoming increasingly evident that DC represent superior antigen-presenting cells not only for CTL induction but also for other types of T-cell responses (15, 16, 19) . This is true for in vivo and in vitro CTL induction, although the present report represents one of the few which have successfully achieved in vitro CTL induction. Satisfactory molecular explanations for the superior APC activity of DC still have not been provided. However, possibilities include high levels of major histocompatibility complex class I and II expression, lower levels of sialic acid residues, and high levels of adhesion molecules (reviewed in reference 28).
It is now well established that exogenously applied nonreplicating antigen becomes capable of inducing CD8+ CTL responses only if the antigen gains access to appropriate compartments within the cytoplasm, where processing may occur (6) . This usually means that the antigen must escape from the endosome, where either complete digestion or processing for class II-restricted T-cell recognition occurs. For protein delivery, several systems which achieve CTL recognition have been described. These include osmotic loading (17) and delivery via immunostimulating complexes (29) , cationic lipids (20, 30) , and pH-sensitive liposomes (19) . The latter approach was presumed to function because such liposomes disrupt and become fusion active upon exposure to the acidifying conditions of the endosomes (33) . Interestingly, primary CTL responses to gB occurred only when antigen was delivered to DC via pH-sensitive liposomes and were absent when DC were merely exposed to soluble gB. This was true both in vivo (Table 2 ) and in vitro (data not shown).
Whereas protein delivery to DC appears to require a specialized delivery system to become CTL inducing, this was not the case for simple peptides. Thus, the 14-aa gB peptide readily induced CTL upon delivery to DC in soluble or liposomal form. However, optimal immunogenicity was obtained when the peptide was derivatized with a triacyl tail and administered via liposomes. Exactly why such peptides effect greater CTL-inducing activity was not determined. However, likely possibilities include more effective use of peptide since the triacylated liposome-associated form may In conclusion, our results demonstrate the necessity of delivering antigen to DC to achieve optimal CTL responses in vitro. Studies are currently under way to establish the phenotype of the CTLs generated and determine the requirement of CD4+ T cells for CTL induction. The culture system we have described promises to be a useful one to guide the selection of peptides for use in vivo to induce a relevant CTL response. It is also evident that if an antigen delivery system is to achieve satisfactory CTL induction in vivo, it should be designed to maximally deliver antigen to DC.
